Citius Pharmaceuticals Aktie [WKN DE: A2DXS0 / ISIN: US17322U2078]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Citius Pharmaceuticals Inc Registered Shs

25.11.24		Citius Pharma Held Productive FDA Meeting To Discuss Phase 3 Mino-Lok Program, Pathway To Approval (RTTNews)
29.07.24		Biotech Stocks Facing FDA Decision In August 2024 (RTTNews)
21.05.24		Citius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok (RTTNews)
18.03.24		Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts (RTTNews)
14.02.24		Citius Pharma Resubmits BLA Of Lymphir To FDA (RTTNews)
02.01.24		Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters (PR Newswire)
02.01.24		Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
09.11.23		Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 (PR Newswire)
31.10.23		Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor (PR Newswire)
24.10.23		TenX To Acquire Citius Pharma's Oncology Subsidiary Via Merger - Quick Facts (RTTNews)
24.10.23		Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. (PR Newswire)
18.09.23		Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 (PR Newswire)
13.09.23		Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir (PR Newswire)
08.09.23		Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ (PR Newswire)
06.09.23		Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 (PR Newswire)
14.08.23		Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
10.08.23		Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial (PR Newswire)
30.07.23		Citius Pharma: FDA Issues CRL For LYMPHIRTM BLA For Patients With Cutaneous T-cell Lymphoma (RTTNews)
29.07.23		Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or ... (PR Newswire)
26.06.23		Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes (PR Newswire)
20.06.23		Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids (PR Newswire)
13.06.23		Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 (PR Newswire)
12.05.23		Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
08.05.23		Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire)
04.05.23		Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire)
24.04.23		Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date (PR Newswire)
03.04.23		Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids (PR Newswire)
30.03.23		Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company (PR Newswire)
13.03.23		Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank (PR Newswire)
08.03.23		Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference (PR Newswire)
10.02.23		Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
11.01.23		Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 (PR Newswire)
22.12.22		Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
01.12.22		Citius: FDA To Review BLA For Denileukin Diftitox - Quick Facts (RTTNews)
01.12.22		Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurre... (PR Newswire)
21.11.22		Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program (PR Newswire)
09.11.22		Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematolog... (PR Newswire)
18.10.22		Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022 (PR Newswire)
06.10.22		Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 (PR Newswire)
28.09.22		Citius Pharma Announces BLA Filing For Denileukin Diftitox - Quick Facts (RTTNews)
28.09.22		Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutan... (PR Newswire)
22.09.22		Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or ... (PR Newswire)
15.09.22		Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute (PR Newswire)
08.09.22		Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
07.09.22		Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
11.08.22		Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
12.07.22		Citius Pharma Plans To Move Forward With Planned BLA Submission For I/ONTAK In H2 (RTTNews)
12.07.22		Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
25.05.22		Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company (PR Newswire)
18.05.22		Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022 (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Ripple steigt deutlich: Neues ATH noch in 2024?

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Diese Aktien empfehlen Experten zu kaufen

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	02.12.2024 10:21
Kaufwert:	EUR
	Hinzufügen Speichern